GRCL — Gracell Biotechnologies Share News
0.000.00%
Last trade - 00:00- $972.69m
- $750.11m
Gracell Biotechnologies gains as blood cancer therapy shows promise
Brief: Gracell Biotechnologies Presents Clinical Data For Fastcar-T Gc012f
Brief: Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results And Provides Corporate Update
Gracell Biotechnologies Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gracell Biotechnologies Doses First Patient In Phase 2 Portion Of Registrational Phase 1/2 Clinical Trial Evaluating Gc007g
Gracell Biotechnologies Inc reports results for the quarter ended in June - Earnings Summary
Gracell Biotechnologies Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Gracell Appoints Dr. Samuel Zhang As Chief Business Officer
U.S. STOCKS ON THE MOVE-Twitter Inc, Netflix Inc, Tesla Inc
Gracell Bio jumps on positive myeloma drug data
Brief: Gracell Biotechnologies To Present Updated Clinical Data On Bcma/Cd19 Dual-Targeting Car-T Gc012f For Relapsed/Refractory Multiple Myeloma At 2022 Asco Annual Meeting
Gracell Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary
Brief: Gracell Biotechnologies Reports Qtrly Loss Per Share $0.07
Gracell Biotechnologies Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Gracell Biotechnologies' Abstract on CAR-T Cell Therapy Accepted for Presentation at 2022 ASCO Annual Meeting
Gracell Biotech surges as BTIG initiates with 'buy'
Gracell Biotech slumps on delaying U.S. regulatory filing for lead drug
Gracell Biotechnologies Inc reports results for the quarter ended in December - Earnings Summary
Brief: Gracell Biotechnologies Reports Fourth Quarter And Full Year 2021 Unaudited Financial Results